Zainab Al-Dhaher1, Sandeep Kapoor2, Ema Saito2,3,4, Scott Krakower2, Lisa David2, Theodore Ake2, John M Kane2,3,4,5, Christoph U Correll2,3,4,5, Maren Carbon2. 1. 1 Department of Psychiatry, New York University Langone Medical Center , New York, New York. 2. 2 Division of Psychiatry Research, The Zucker Hillside Hospital , North Shore-Long Island Jewish Health System, Glen Oaks, New York. 3. 3 Department of Psychiatry, Hofstra North Shore LIJ School of Medicine , Hempstead, New York. 4. 4 Department of Molecular Medicine, Hofstra North Shore LIJ School of Medicine , Hempstead, New York. 5. 5 Center for Psychiatric Neuroscience , The Feinstein Institute for Medical Research, Manhasset, New York.
Abstract
OBJECTIVE: To assess activating and tranquilizing effects of second-generation antipsychotics (SGAs) in youth. METHODS: As part of the naturalistic inception cohort study, "Second-generation Antipsychotic Treatment Indication, Effectiveness and Tolerability in Youth (SATIETY)," subjective ratings of activating and tranquilizing symptoms were obtained monthly for 3 months from antipsychotic-naïve youth initiating SGAs using the Treatment Emergent Symptoms Scale (TESS). Discontinuation rates, and TESS-reported symptom rates, and severity were related to clinical and treatment parameters. Two compound measures of TESS were defined: presence of any daytime activating (ACTIVATION+) and sedating symptoms (SEDATION+). RESULTS: In 327 antipsychotic-naïve youth originally initiating the four studied SGAs, discontinuation due to sedation was marginally highest with quetiapine (13.0%) followed by olanzapine (7.3%), risperidone (4.2%), and aripiprazole (2.0%) (p = 0.056). Two hundred fifty-seven antipsychotic-naïve youth (13.8 ± 3.6 years, male = 57.8%) initiated aripiprazole (n = 40), olanzapine (n = 45), quetiapine (n = 36), or risperidone (n = 135) and completed ≥1 postbaseline follow-up visit. Baseline prevalence of ACTIVATION+ (39.9%) or SEDATION+ (54.1%) did not differ between SGAs. Rates of both compound measures changed significantly over time (decrease for ACTIVATION+, p = 0.0002; increase for SEDATION+, p < 0.0001) with slight differences between SGAs, explained by lower rates of ACTIVATION+ with olanzapine (p = 0.002) and slightly higher rates of ACTIVATION+ with aripiprazole (p = 0.018) during follow-up, and lower rates of SEDATION+ with aripiprazole (p = 0.018). All four SGAs reduced insomnia (p = 0.001) and increased hypersomnia (p < 0.001). Postbaseline prevalence of drowsiness, the most frequent, but mild TESS complaint was 85%, without SGA differences. Younger age was associated with activating symptoms, higher age with sedating symptoms, and lower baseline functioning increased both. Psychomotor retardation rates were high in subjects with schizophrenia-spectrum disorders, whereas stimulant comedication was associated with psychomotor activation, regardless of diagnosis. CONCLUSIONS: Although small SGA-specific differences in activating/sedating compound side effect measures were noted, independent predictors of single TESS ratings included clinical parameters, rather than specific SGAs, suggesting a need for carefully individualized treatment strategies.
OBJECTIVE: To assess activating and tranquilizing effects of second-generation antipsychotics (SGAs) in youth. METHODS: As part of the naturalistic inception cohort study, "Second-generation Antipsychotic Treatment Indication, Effectiveness and Tolerability in Youth (SATIETY)," subjective ratings of activating and tranquilizing symptoms were obtained monthly for 3 months from antipsychotic-naïve youth initiating SGAs using the Treatment Emergent Symptoms Scale (TESS). Discontinuation rates, and TESS-reported symptom rates, and severity were related to clinical and treatment parameters. Two compound measures of TESS were defined: presence of any daytime activating (ACTIVATION+) and sedating symptoms (SEDATION+). RESULTS: In 327 antipsychotic-naïve youth originally initiating the four studied SGAs, discontinuation due to sedation was marginally highest with quetiapine (13.0%) followed by olanzapine (7.3%), risperidone (4.2%), and aripiprazole (2.0%) (p = 0.056). Two hundred fifty-seven antipsychotic-naïve youth (13.8 ± 3.6 years, male = 57.8%) initiated aripiprazole (n = 40), olanzapine (n = 45), quetiapine (n = 36), or risperidone (n = 135) and completed ≥1 postbaseline follow-up visit. Baseline prevalence of ACTIVATION+ (39.9%) or SEDATION+ (54.1%) did not differ between SGAs. Rates of both compound measures changed significantly over time (decrease for ACTIVATION+, p = 0.0002; increase for SEDATION+, p < 0.0001) with slight differences between SGAs, explained by lower rates of ACTIVATION+ with olanzapine (p = 0.002) and slightly higher rates of ACTIVATION+ with aripiprazole (p = 0.018) during follow-up, and lower rates of SEDATION+ with aripiprazole (p = 0.018). All four SGAs reduced insomnia (p = 0.001) and increased hypersomnia (p < 0.001). Postbaseline prevalence of drowsiness, the most frequent, but mild TESS complaint was 85%, without SGA differences. Younger age was associated with activating symptoms, higher age with sedating symptoms, and lower baseline functioning increased both. Psychomotor retardation rates were high in subjects with schizophrenia-spectrum disorders, whereas stimulant comedication was associated with psychomotor activation, regardless of diagnosis. CONCLUSIONS: Although small SGA-specific differences in activating/sedating compound side effect measures were noted, independent predictors of single TESS ratings included clinical parameters, rather than specific SGAs, suggesting a need for carefully individualized treatment strategies.
Authors: Eduard Vieta; Gemma Parramon; Elena Padrell; Evaristo Nieto; Anabel Martinez-Arán; Barbara Corbella; Francesc Colom; Maria Reinares; Jose M Goikolea; Carla Torrent Journal: Bipolar Disord Date: 2002-10 Impact factor: 6.744
Authors: Linmarie Sikich; Robert M Hamer; Robert A Bashford; Brian B Sheitman; Jeffrey A Lieberman Journal: Neuropsychopharmacology Date: 2004-01 Impact factor: 7.853
Authors: Magali Haas; Alan S Unis; Jorge Armenteros; Margaret D Copenhaver; Jorge A Quiroz; Stuart F Kushner Journal: J Child Adolesc Psychopharmacol Date: 2009-12 Impact factor: 2.576
Authors: Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan Journal: Can J Psychiatry Date: 2017-07-13 Impact factor: 4.356
Authors: Gonzalo Salazar de Pablo; Daniel Guinart; Barbara A Cornblatt; Andrea M Auther; Ricardo E Carrión; Maren Carbon; Sara Jiménez-Fernández; Ditte L Vernal; Susanne Walitza; Miriam Gerstenberg; Riccardo Saba; Nella Lo Cascio; Martina Brandizzi; Celso Arango; Carmen Moreno; Anna Van Meter; Paolo Fusar-Poli; Christoph U Correll Journal: Front Psychiatry Date: 2020-10-21 Impact factor: 4.157